Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of CB-839 in Combination With Niraparib in Platinum Resistant BRCA-wild-type Ovarian Cancer Patients

NCT03944902 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT03944902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03944902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of CB-839 in Combination With Niraparib in Platinum Resistant BRCA-wild-type Ovarian Cancer Patients
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Terminated
Start date
September 1, 2021
Completion date
January 5, 2022
Enrollment
1 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, resistant brca wild-type ovarian cancer